Skip to main content
. 2020 Jun 30;16:607–615. doi: 10.2147/TCRM.S255365

Table 3.

Drug-Related AEs

AE FUL (n=124) EVE-EXE (n=44)
Any Grade (%) Grade 3/4 (%) Any Grade (%)
Hematologic
 Anemia 2 (1.6) 0 6 (13.6) 1 (2.7)
 Thrombocytopenia 0 0 5 (11.4) 2 (4.5)
 Leukopenia 0 0 2 (4.5) 0
Non-Hematologic
 Stomatitis 0 0 25 (56.8) 5 (11.4)
 Fatigue 2 (1.6) 0 11 (25) 1 (2.3)
 Infection 0 0 11 (25) 2 (4.5)
 Rash 0 0 8 (18.2) 2 (2.4)
 Edema 1 (0.9) 0 6 (13.6) 0
 Cough 0 0 6 (13.6) 0
 Diarrhea 0 0 5 (11.4) 0
 Non-infectious pneumonitis 0 0 5 (11.4) 0
 Pyrexia 0 0 4 (9.1) 0
 Anorexia 0 0 4 (9.1) 0
 Hypertension 0 0 3 (6.8) 1 (2.3)
 Weight loss 0 0 2 (4.5) 0
 Joint disorders 6 (5.0) 0 0 0
 Injection site reactions 5 (4.0) 0 0 0
 Gastrointestinal disturbances 3 (2.4) 0 0 0
 Hot flashes 2 (1.6) 0 0 0
 Biological events 0 0
 Hyperglycemia 2 (2.7) 0 10 (22.7) 0
 ALT increased 6 (8.2) 0 7 (15.9) 1 (2.3)
 AST increased 6 (8.2) 0 7 (15.9) 0
 Hyperlipidemia 0 0 4 (9.1) 0

Abbreviations: AE, adverse events; FUL, fulvestrant; EVE-EXE, everolimus plus exemestane; ALT, alanine aminotransferase; AST, aspartate aminotransferase.